

DESCRIPTION

Source Chinese Hamster Ovary cell line, CHO-derived
Arg72-Asp318, with an N-terminal 6-His tag
Accession # XP_008769150

N-terminal Sequence Analysis His

Predicted Molecular Mass 29 kDa

SPECIFICATIONS

SDS-PAGE 33-38 kDa, reducing conditions

Activity Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells. The ED₅₀ for this effect is 2.5-15 ng/mL in the presence of 2.5 µg/mL of a cross-linking antibody, Mouse Anti-polyHistidine Monoclonal Antibody (Catalog # [MAB050R](#)).

Endotoxin Level <0.10 EU per 1 µg of the protein by the LAL method.

Purity >85%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Formulation Lyophilized from a 0.2 µm filtered solution in NaH₂PO₄, NaCl and EDTA with BSA as a carrier protein. See Certificate of Analysis for details.

PREPARATION AND STORAGE


Reconstitution Reconstitute at 100 µg/mL in PBS containing at least 0.1% human or bovine serum albumin.

Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

DATA



BACKGROUND

RANK L (receptor activator of NF-kappa B ligand), also called TRANCE (TNF-related activation-induced cytokines), OPGL (osteoprotegerin ligand), or ODF (osteoclast differentiation factor), is a 39-45 kDa type II transmembrane (TM) protein in the tumor necrosis factor family, designated TNFSF11 (1-5). RANK L, produced by osteoblasts and bone marrow stromal cells, is required for differentiation of osteoclasts and stimulates bone resorption (4, 6). It is also produced by activated T cells and augments dendritic cell stimulation; RANK L^{-/-} mice lack lymph nodes and have impaired thymocyte development (1-3, 6). The rat RANK Ligand cDNA encodes a type II transmembrane protein of 318 amino acids with a predicted cytoplasmic domain of 47 amino acids, a 21 amino acids transmembrane region, and an extracellular domain of 250 amino acids. The extracellular domain contains two potential N-linked glycosylation sites. Rat and human RANK Ligand and rat and mouse RANK Ligand share 83% and 95% amino acid identity respectively. RANK L can stimulate human osteoclast differentiation (4). Like most TNF family members, RANK L can form trimers (1). Soluble 31, 25 and 24 kDa forms of RANK L can be created by usage of alternate start sites at aa 74 or 146, or proteolytic cleavage by osteoblast- or stromal cell-derived ADAM10 (after aa 139) or MMP14 (aa 146), or bone metastatic prostate tumor-derived MT1-MMP (aa 146) (5, 7, 8). Both TM and soluble extracellular RANK L act by engaging RANK receptors and are antagonized by the decoy receptor, OPG (osteoprotegerin) (2, 5). In resting cells, the majority of RANK L is stored in secretory lysosomes (9). In mammary epithelia, RANK L is up-regulated by pregnancy hormones and is essential for the formation of a lactating mammary gland (10). In the brain, astrocyte RANK L mediates body temperature regulation (11). Pathologically, RANK L is thought to mediate post-menopausal osteoporosis, vascular calcification, progesterin-induced breast cancer, cancer-induced bone disease, and osteopetrosis (in RANK L deficiencies) (12-16).

References:

1. Leibbrandt, A. and J.M. Penninger (2008) *Ann. N. Y. Acad. Sci.* **1143**:123.
2. Wong, B.R. *et al.* (1997) *J. Biol. Chem.* **272**:25190.
3. Anderson, D.M. *et al.* (1997) *Nature* **390**:175.
4. Lacey, D.L. *et al.* (1998) *Cell* **93**:165.
5. Hikita, A. *et al.* (2006) *J. Biol. Chem.* **281**:36846.
6. Kong, Y-Y. *et al.* (1999) *Nature* **397**:315.
7. Accession # NP_143026 and EAX08679.
8. Sabbota, A.L. *et al.* (2010) *Cancer Res.* **70**:5558.
9. Aoki, S. *et al.* (2010) *J. Bone Miner. Res.* **25**:1907.
10. Fata, J.E. *et al.* (2000) *Cell* **103**:41.
11. Hanada, R. *et al.* (2009) *Nature* **462**:505.
12. Osako, M.K. *et al.* (2010) *Circ. Res.* **107**:466.
13. Schramek, D. *et al.* (2010) *Nature* **468**:98.
14. Gonzalez-Suarez, E. *et al.* (2010) *Nature* **468**:103.
15. Dougall, W.C. and M. Chaisson (2006) *Cancer Metastasis Rev.* **25**:541.
16. Sobacchi, C. *et al.* (2007) *Nat. Genet.* **39**:960.